Novartis Ag (NVS) Change in Receivables (2022 - 2026)

Novartis Ag's Change in Receivables history runs 5 years deep, the most recent figure standing at -$504.0 million for Q1 2026.

• In Q1 2026, Change in Receivables changed N/A year-over-year to -$504.0 million; the TTM figure through Mar 2026 stood at -$256.0 million (changed N/A YoY), while the FY2025 annual figure was -$94.0 million, changed N/A from the prior year.
• Change in Receivables came in at -$504.0 million for Q1 2026 at Novartis Ag, down from -$94.0 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $328.0 million in Q3 2024 to a low of -$920.0 million in Q1 2024.
• A 5-year average of -$283.8 million and a median of -$136.0 million in 2022 frame the typical range for Change in Receivables.
• Across the five-year window, Change in Receivables jumped 380.34% in 2024 and plunged 158.02% in 2025, its largest moves.
• Novartis Ag's Change in Receivables stood at -$825.0 million in 2022, then jumped by 85.82% to -$117.0 million in 2023, then jumped by 238.46% to $162.0 million in 2024, then slumped by 158.02% to -$94.0 million in 2025, then slumped by 436.17% to -$504.0 million in 2026.
• According to Business Quant data, Change in Receivables over the past three periods registered -$504.0 million, -$94.0 million, and $180.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison